Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Japan To Compensate Hepatitis C Victims, Leave Drug Makers Liable (Japan)

This article was originally published in PharmAsia News

Executive Summary

The Japanese government plans to enact legislation early in the new year to compensate some of an estimated 1,000 patients infected with hepatitis C after being given tainted blood products. The proposed bill would let the courts decide who would be eligible, as well as the fate of drug makers responsible for the suspect blood products. Under the bill being discussed by legislators, government compensation would be confined to patients given fibrinogen and hemostatic agents, but not to those infected through transfusions. Prime Minister Yasuo Fukuda apologized in person to four of the 200 people who filed suits. (Click here for more



Ask The Analyst

Please Note: Click here for more information on the Ask the Analyst service.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts